About the Dermatologic Drug Development Session
Dermatologic drug development involves the creation and testing of new medications specifically designed to treat a wide range of skin conditions, from common issues like acne and eczema to more complex diseases such as psoriasis and skin cancer. The process of developing dermatologic drugs requires a thorough understanding of skin biology, as well as how drugs interact with the skin's layers and systems. Advances in dermatologic drug development have led to targeted therapies, such as biologics and topical immunomodulators, which offer more precise and effective treatments with fewer side effects compared to traditional options. In addition to systemic treatments, innovations in drug delivery systems, such as nanoparticles and liposomes, are improving the effectiveness and penetration of topical treatments. Dermatologic drug development also focuses on personalized medicine, tailoring treatments to individual patients based on genetic, environmental, and lifestyle factors. As research progresses, new therapies continue to emerge, offering better management and potential cures for a range of dermatological diseases.
Featured Speakers — Dermatologic Drug Development 2027
Speaker lineup for this track will be announced soon.
Browse all speakers →Recent Research Presented at Dermatologic Drug Development Sessions
Selected abstracts from this track will be published here.
Related Scientific Sessions at IDC 2027
Why Attend the Dermatologic Drug Development Conference 2027
Present Your Research
Oral and poster slots for original Dermatologic Drug Development work, reviewed by the scientific committee.
Network Globally
Meet researchers, clinicians, and industry leaders from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Dermatologic Drug Development research and practice.
Hybrid Flexibility
Attend in person in Rome or join virtually — same program, same certificate.
Join IDC 2027 for the Dermatologic Drug Development track
Oral and poster slots for your work — in person in Rome or online. Not presenting? Attend as a delegate to learn from the field.
Dermatologic Drug Development Conference 2027 — FAQs
What is the Dermatologic Drug Development track at IDC 2027?
The Dermatologic Drug Development track is a dedicated stream within IDC 2027 covering the latest research, clinical innovation, and best practice in Dermatologic Drug Development. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Dermatologic Drug Development sessions?
Researchers, clinicians, educators, doctoral students, and industry leaders with an interest in Dermatologic Drug Development are all welcome — whether presenting or attending.
Can I present my research in the Dermatologic Drug Development track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Dermatologic Drug Development sessions?
Yes. IDC 2027 is a hybrid conference — attend the Dermatologic Drug Development track in person in Rome or join live online, with on-demand access afterward.
Join the IDC 2027 delegation
Rome · June 21–23, 2027 · Hybrid · in-person & virtual
Attend without presenting.